NCT06978101 is a clinical trial of POAG group in Visual Field, sponsored by Assiut University.

Who is sponsoring NCT06978101?

NCT06978101 is sponsored by Assiut University.

What drugs are being tested in NCT06978101?

Interventions in NCT06978101: POAG group, Control group.

What condition does NCT06978101 study?

NCT06978101 studies Visual Field, OCT Angiography, Chorioretinal Changes, Primary Open Angle Glaucoma.

Is NCT06978101 still recruiting?

NCT06978101 is currently completed. Last updated 18 May 2025.

Last reviewed 2025-05-18 · How we verify

NCT06978101

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Visual Field Changes and OCT Angiographic Chorioretinal Changes in Patients With Primary Open Angle Glaucoma

Completed Last updated 18 May 2025

What this trial tests

trial testing POAG group in Visual Field in 100 participants. Completed in 30 December 2023.

Timeline

30 December 2021

Primary endpoint
30 December 2023

30 December 2023

Quick facts

Lead sponsor	Assiut University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	100
Start date	30 December 2021
Primary completion	30 December 2023
Estimated completion	30 December 2023
Sites	1 location across Egypt

Drugs / interventions tested

POAG group
Control group — full drug profile →

Conditions studied

Visual Field — all drugs for Visual Field →
OCT Angiography — all drugs for OCT Angiography →
Chorioretinal Changes — all drugs for Chorioretinal Changes →
Primary Open Angle Glaucoma — all drugs for Primary Open Angle Glaucoma →

Sponsor

Assiut University

Who can join

18 and older, any sex, with Visual Field or OCT Angiography. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aimed to assess the correlation between visual field changes and optical coherence tomography (OCT) angiography changes of retinal nerve fiber layer in patients with primary open angle glaucoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06978101 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 18 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06978101.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing